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The Aquaporin-4 (AQP4) water channel contributes to brain water
homeostasis in perivascular astrocyte endfeet where it is concen-
trated. We postulated that AQP4 is tethered at this site by binding
of the AQP4 C terminus to the PSD95-Discs large-ZO1 (PDZ) domain
of syntrophin, a component of the dystrophin protein complex.
Chemical cross-linking and coimmunoprecipitations from brain
demonstrated AQP4 in association with the complex, including
dystrophin, -dystroglycan, and syntrophin. AQP4 expression was
studied in brain and skeletal muscle of mice lacking -syntrophin
(-Syn/). The total level of AQP4 expression appears normal in
brains of -Syn/ mice, but the polarized subcellular localization
is reversed. High-resolution immunogold analyses revealed that
AQP4 expression is markedly reduced in astrocyte endfeet mem-
branes adjacent to blood vessels in cerebellum and cerebral cortex
of -Syn/ mice, but is present at higher than normal levels in
membranes facing neuropil. In contrast, AQP4 is virtually absent
from skeletal muscle in -Syn/ mice. Deletion of the PDZ-binding
consensus (Ser-Ser-Val) at the AQP4 C terminus similarly reduced
expression in transfected cell lines, and pulse–chase labeling dem-
onstrated an increased degradation rate. These results demon-
strate that perivascular localization of AQP4 in brain requires
-Syn, and stability of AQP4 in the membrane is increased by the
C-terminal PDZ-binding motif.
Aquaporin water channel proteins are responsible for thehigh membrane water permeabilities of the tissues where
they are expressed. The physiological significance of the ten
mammalian aquaporins is emerging from studies of naturally
occurring mutants and mice carrying targeted disruptions in
aquaporin genes, with phenotypes ranging from congenital
cataracts to nephrogenic diabetes insipidus (1). Each aquaporin
has characteristic subcellular localization and tissue expression
patterns that determine its physiological roles, but the mecha-
nisms responsible for these complex patterns are largely un-
known. In the mammalian central nervous system, AQP4 is
concentrated in astrocyte endfeet membranes facing blood–
brain and brain–cerebrospinal f luid interfaces (2, 3). AQP4 is
also expressed in sarcolemma of fast-twitch fibers in skeletal
muscle (2) and in basolateral membranes of collecting duct
epithelium (4), sites where the dystrophin protein complex is
expressed (5–8).
Identified as the gene mutated in DuchenneBecker muscular
dystrophies (9), dystrophin is part of a large membrane assembly
connecting the cytoskeleton to the extracellular matrix (10).
Dystrophin forms a bridge between filamentous actin and the
transmembrane protein -dystroglycan, which is associated with
a lamininagrin-binding protein, -dystroglycan. On the cyto-
plasmic side of the complex, dystrophin binds to dystrobrevin,
providing a scaffold for binding up to four syntrophin molecules
(11, 12). Syntrophins are a family of five proteins (, 1, 2, 1,
2) containing two pleckstrin homology domains, a PSD95-Discs
large-ZO1 (PDZ) domain, and a C-terminal syntrophin-unique
region (8). The PDZ domain serves as an adaptor for recruiting
membrane channels, receptors, kinases, and other signaling
proteins. Tissue-specific variations in the dystrophin complex are
in part caused by different syntrophins. The -syntrophin iso-
form is expressed primarily in skeletal and cardiac muscle, and
at lower levels in brain (11, 13).
Localization of the dystrophin protein complex in perivascular
astrocyte endfeet, skeletal muscle sarcolemma, and renal col-
lecting duct suggests association with AQP4. AQP4 has the
C-terminal sequence Ser-Ser-Val (tSSV), a sequence potentially
capable of binding to PDZ domains in proteins such as syntro-
phins (14–16). AQP4 expression is markedly reduced in the
skeletal muscle of mdx mice, which lack full-length dystrophin
and associated proteins (17). Here we show that expression and
subcellular localization of AQP4 depend on association with the
dystrophin complex through a tSSV-PDZ-mediated interaction
with -syntrophin.
Materials and Methods
Coimmunoprecipitation. Sprague–Dawley rat cerebellum (130 mg)
was homogenized by Potter–Elvehjem at 4°C in 5 ml of 7.5 mM
sodium phosphate (pH 7.0)0.25 M sucrose5 mM EDTA5 mM
EGTA, with Complete Protease Inhibitor Cocktail (Roche
Diagnostics). After a 10-min 1,000  g spin at 4°C, supernatants
were incubated 30 min at 4°C with 150 M dithiobis(succinimi-
dyl propionate) (Sigma–Aldrich). Then 1.0% Triton X-100, 0.5%
sodium deoxycholate, and 150 mM NaCl were added for 30 min.
One-third of the sample was incubated for 4 h at 4°C with
anti-AQP4 antibody (3 g), anti-syntrophin hybridoma culture
supernatant (20 l), or rabbit IgG (3 g). Immune complexes
were adsorbed to 80 l of protein A-Sepharose CL-4B (Sigma–
Aldrich), washed four times at 4°C in 20 mM Tris (pH 8.0), 1.0%
Triton X-100, 0.5% sodium deoxycholate, 150 mM NaCl, 5 mM
EDTA, and 5 mM EGTA, and once with salt-free buffer.
Immune complexes were eluted with 50 l of SDSPAGE
sample buffer at 37°C for 30 min.
Immunoblotting. Immunoprecipitates, cell membrane fractions,
and lysates were analyzed by SDSPAGE immunoblotting (18).
Skeletal muscle AQP4 was immunoprecipitated from tibialis
anterior and extensor digitorum longus. Mouse monoclonal
MANEX7374A was used to detect Dp71 in anti-AQP4 immu-
noprecipitate; rabbit polyclonal 331 was used for Dp71 detec-
tion in anti-Syn immunoprecipitate.
Antibodies. Rabbit polyclonal antibody to AQP4 (4, 18), pan-
syntrophin mouse monoclonal SYN1351 (19), -Syn-specific
rabbit polyclonal SYN17 (11), and dystrophin polyclonal 331
2723 (19) were used. Dystrophin monoclonal MANEX7374A
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(clone 10A11) was from Glenn Morris (North East Wales
Institute, Wrexham, U.K.). Commercial monoclonal antibodies
to -dystroglycan (VIA4–1; Upstate Biotechnology, Lake
Placid, NY) and -dystroglycan (43DAG18D5; NovoCastra,
Newcastle, U.K.) were used.
Electron Microscopy. Mice were perfused through the heart with
4% formaldehyde in phosphate buffer containing 0.2% picric
acid at pH 6.0, then pH 10.0. Brains were cut into 0.5- to 1.0-mm
slices, cryoprotected, quick-frozen in liquid propane (170°C),
and subjected to freeze substitution. Specimens were embedded
in methacrylate resin (Lowicryl HM20) and polymerized by UV
light below 0°C. Ultrathin sections incubated with antibodies to
AQP4 (0.5 gml) or -Syn (10 gml) followed by goat
anti-rabbit antibody coupled to colloidal gold were examined
using a Philips CM 10 electron microscope at 60 kV.
Fluorescence Microscopy. Immunofluorescence labeling of unfixed
skeletal muscle was performed on 8-m cryosections of quad-
riceps femoris (11, 20). AQP4-transfected cell lines grown on
glass cover slips (HEK293 and MDCK cells) or Nalge Nunc
Permanox chamber slides (CHO-K1 cells) were fixed with
formaldehyde, permeabilized with Triton X-100, and incubated
with the AQP4 antibody (0.15 gml) followed by Alexa 488-
conjugated goat anti-rabbit IgG (2.0 gml, Molecular Probes).
Confocal microscopy used a Zeiss LSM 410.
Transfected Cell Lines. HEK293 cells and CHO-K1 cells (Ameri-
can Type Culture Collection, Manassas, VA) and type II MDCK
cells (8) were used. HEK293 and MDCK cells were cultured in
90% Dulbecco’s modified Eagle’s medium (DMEM; Life Tech-
nologies, Rockville, MD)10% fetal bovine serum. CHO-K1
cells were cultured in 90% F-12K (Kaighn’s modified F-12; Life
Technologies)10% fetal bovine serum. AQP4 expression plas-
mids were constructed from the pCI-neo vector (Promega) and
cDNA sequences for the wild-type M1 (amino acids 1–323) and
M23 (amino acids 23–323) isoforms of rat AQP4 (GenBank
U14007) or for M1 and M23 isoforms lacking the C-terminal
SSV (amino acids 1–320 and amino acids 23–320). Cell lines
transfected with Lipofectamine Plus (Life Technologies) were
selected for 14 days in medium with 700 gml Geneticin and
maintained in 200 gml Geneticin.
Reverse Transcription (RT)-PCR. Total RNA was isolated by extrac-
tion with phenol and guanidine isothiocyanate (Trizol; Life
Technologies). Single-stranded cDNA was synthesized with re-
verse transcriptase and oligo(dT)18 primer (Advantage RT-for-
PCR Kit; CLONTECH). cDNA was used for PCR with oligo-
nucleotide primers to amplify segments from AQP4, -actin, and
neomycin resistance (NeoR) genes. PCR controls used RNA
without RT.
Metabolic Labeling. Stably transfected HEK293 cells in 60-mm
dishes were incubated for 30 min in methionine-free DMEM
supplemented with L-glutamine and for 60 min in methionine-
free DMEM supplemented with L-glutamine and 0.4 mCiml (1
Ci  37 GBq) L-[35S]methionine. Labeling medium was then
replaced with DMEM. At chase times, cells were harvested in 1.0
ml of solubilization buffer [20 mM Tris (pH 8.0)200 mM
NaCl1% Triton X-1001% sodium deoxycholate0.1% SDS
5.0 mM EDTA5.0 mM EGTAComplete Protease Inhibitor
Cocktail (Roche)]. Lysates were incubated with 3 g of AQP4
antibody for 1 h at 4°C. Immune complexes were precipitated
with protein A-Sepharose for SDSPAGE autoradiography.
Results
Association of AQP4 with the Dystrophin Protein Complex. PDZ
proteins bind directly to a motif of three to five residues at the
C terminus of certain membrane proteins. The chemical cross-
linking agent dithiobis(succinimidyl propionate) was used to
stabilize this association before immunoprecipitation with anti-
AQP4 or with pan-specific anti-syntrophin. After cleaving the
cross-linker with DTT, SDSPAGE immunoblotting revealed
AQP4 in the anti-syntrophin immunoprecipitate (Fig. 1A).
-dystroglycan and the astrocyte isoform of dystrophin, Dp71
(6), were also present. Likewise, the anti-AQP4 immunoprecipi-
tate contained -dystroglycan and Dp71; however, presence of
syntrophins could not be evaluated because they comigrate on
SDSPAGE with the IgG heavy chain. Coimmunoprecipitation
of AQP4 with multiple dystrophin-associated proteins and the
known reduction of AQP4 in the skeletal muscle of mdx mice
(17) strongly suggest that these proteins reside in a large
complex.
AQP4 Expression in -Syn/ Mice. To determine whether -
Syntrophin binds to AQP4 in vivo, we analyzed AQP4 expression
in tissues of mice with targeted disruption of the gene for -Syn
(20), which is normally expressed in brain and skeletal muscle
(11, 21). Dystrophin expression is normal in these mice, even
though -Syn is absent (20). Immunoblots revealed that total
AQP4 expression is unchanged in brain but is markedly reduced
in skeletal muscle (Fig. 1B).
High-resolution, immunogold electron microscopy of rat brain
has shown AQP4 to be concentrated in astrocyte membranes
apposed to blood vessels but nearly absent in membranes away
from the endothelial basal lamina (3). Cerebellum from wild-
type -Syn/ (data not shown) or heterozygous -Syn/ mice
exhibits this same pattern (Fig. 2A). In contrast, the pattern is
reversed in cerebellum from -Syn/ animals, with perivascular
astrocyte processes showing stronger immunogold labeling along
the membrane facing the neuropil than along the membrane
facing the blood vessel (Fig. 2B). Immunogold labeling demon-
strated that -Syn in astrocytes is concentrated in membranes in
direct contact with endothelial basal lamina, similar to AQP4
(Fig. 2C). -Syn antibody labeling is entirely absent in -Syn/
cerebellum (Fig. 2D). Elsewhere in brain, AQP4 is concentrated
Fig. 1. Immunoblots of brain and skeletal muscle. (A) Coimmunoprecipita-
tion (IP) of AQP4 with syntrophin and other dystrophin-associated proteins
from dithiobis(succinimidyl propionate)-stabilized rat cerebellum homoge-
nate by AQP4 or pan-syntrophin antibodies. Immunoblots (IB) showed specific
reactions with antibodies to AQP4 (major band, 32 kDa), -dystroglycan (DG,
43 kDa), or dystrophin isoform (Dp71, 71 kDa). Nonspecific IgG immunopre-
cipitates were nonreactive. (B) AQP4 immunoblots of cerebellum and cerebral
cortex membranes (20 g protein per lane) and AQP4 immunoprecipated
from skeletal muscle of wild-type (wt) mice or mice lacking -Syn (Syn/).







Fig. 2. Immunogold electron micrographs of cerebellum from heterozygous (-Syn/) and -Syn-null (-Syn/) mice incubated with antibodies to AQP4 (AQP4
Ab) or -Syn (Syn Ab). (A and B) AQP4 immunolabeling of astrocyte perivascular endfeet in membranes facing endothelial basal lamina (paired arrowheads) or
membranes facing neuropil (double arrowheads). (C and D) -Syn immunolabeling is similar to AQP4 in wild-type (wt) mice but is absent in -Syn/ mice. End,
capillary endothelial cell; N, nucleus; L, lumen. (Scale bars, 0.5 m.)
14110  www.pnas.orgcgidoi10.1073pnas.241508198 Neely et al.
in astrocyte membranes adjacent to endothelial basal lamina in
cerebral cortex from wild-type mice (Fig. 3A), whereas AQP4
expression is strongly reduced in this membrane in cortex from
-Syn/ animals (Fig. 3B).
AQP4 is also expressed in sarcolemma of fast-twitch muscle
fibers (2), as contained in quadriceps femoris. Immunolabeling
revealed AQP4 in muscle from wild-type mice but almost none
in -Syn/ muscle (Fig. 4), although residual AQP4 was local-
ized to the sarcolemma. Thus, although proper distribution of
AQP4 depends on -Syn in brain, overall expression of AQP4
requires -Syn in skeletal muscle.
Expression of AQP4 Lacking C Terminus. Because the C terminus of
AQP4 (-SSV-COOH) conforms to the consensus for a PDZ-
binding site, we reasoned that -syntrophin may stabilize plasma
membrane expression of AQP4 through a direct tSSV–PDZ
interaction. To determine whether the AQP4 C terminus actu-
ally binds to syntrophins or other PDZ proteins, we compared
the expression of wild-type (wt) AQP4 to that of AQP4 lacking
three amino acids at the C terminus (AQP4 SSV) in transfected
cell lines expressing syntrophins and other dystrophin-associated
proteins (8, 22). Immunofluorescence confocal microscopy dem-
onstrated wt AQP4 and AQP4 SSV in plasma membranes of
the cell lines, and both were restricted to basolateral domains in
polarized MDCK cells (Fig. 5A Insets). Thus, the tSSV is not
essential for targeting of AQP4.
AQP4 expression in stably transfected HEK293 cells was
evaluated further to determine whether the tSSV influences
Fig. 4. Confocal anti-AQP4 immunofluorescence of skeletal muscle from
wild-type (wt) and -Syn-null (-Syn/) mice. Quadriceps femoris labeled
with AQP4 and -Syn antibodies reveals nearly complete loss of AQP4 from
fast-twitch fibers in the absence of -Syn.
Fig. 3. Anti-AQP4 immunogold electron micrographs of cerebral cortex from (A) wild-type (wt) and (B) -Syn-null (-Syn/) mice. Anti-AQP4 labeling of
astrocyte endfeet in membranes facing endothelial basal lamina (paired arrowheads) or membranes facing neuropil (double arrowheads). End, capillary
endothelial cell; N, nucleus; L, lumen. (Scale bars, 0.5 m.)







AQP4 stability. Immunoblots revealed a reduction in overall
expression of AQP4 SSV when compared with wt AQP4 (Fig.
5B). RT-PCR demonstrated that AQP4 mRNA and -tubulin
mRNA levels were equivalent in both cell lines. Similar trans-
fection efficiencies were confirmed by levels of NeoR (Fig. 5C).
Stability of wt AQP4 and AQP4 SSV were also compared by
[35S]methionine pulse– chase labeling of the transfected
HEK293 cells. The exponential decline of signal showed a
half-life of 8 h for AQP4 SSV compared with 24 h for wt
AQP4 (Fig. 6). Thus, the C-terminal SSV determines overall
expression of AQP4 by influencing the degradation rate.
Discussion
Polarized expression of AQP4 at the blood–brain interface
depended on the dystrophin-associated PDZ protein -Syn.
-Syn influences the overall level of AQP4 expression in skeletal
muscle, although sarcolemmal targeting of AQP4 can occur in its
absence. Likewise, in transfected cell lines, the AQP4 C-terminal
SSV is required for high-level AQP4 expression but not for
plasma membrane targeting. Decreased expression of AQP4
SSV is due to an increased degradation rate. -Syn most likely
regulates AQP4 expression by stabilizing the protein in the
plasma membrane through a tSSV-PDZ-mediated interaction,
similar to the mechanism stabilizing plasma membrane retention
of the epithelial -aminobutyric acid transporter BGT1 by the
PDZ protein LIN7 (23).
Targeting of AQP4 to basolateral domains may involve C-
terminal di-leucine or tyrosine-based motifs (S. Le Maout,
personal communication). While our work was being completed,
independent studies suggested that subcellular localization of
AQP4 is altered in -Syn/ skeletal muscle without a change in
total expression estimated by immunoblot (24). Although we
cannot explain this discrepancy, we have not been able to detect
AQP4 in immunoblots of whole membranes from skeletal mus-
cle without prior immunoprecipitation (18).
Consistent with a PDZ-mediated interaction of -Syn with
AQP4, ongoing studies indicate that transgenic mice overex-
pressing a dominant-negative mutant -Syn (lacking the PDZ
domain) also have reduced AQP4 expression in skeletal muscle
(25). Nevertheless, we have not been able to detect direct binding
between peptides or recombinant fusion proteins representing
the AQP4 C terminus and -Syn PDZ domain in blot overlays,
ELISAs, or surface plasmon resonance assays (data not shown).
We have also attempted without success to identify an interme-
diate linker protein by yeast two-hybrid screening and ELISAs
involving the PDZ domains of various candidates (data not
shown). These results are consistent with requirement for an
accessory factor, a posttranslational modification, or binding by
multiple sites, as was recently shown for the interaction between
2-syntrophin and the ICA512 transmembrane protein (26).
The need for chemical cross-linking before detergent solubi-
lization to capture the interaction between AQP4 and the
dystrophin complex may indicate that the association is labile.
Although our AQP4-transfected cell lines express syntrophins
and other dystrophin-associated proteins, we were unable to
demonstrate cross-linking between AQP4 and the dystrophin-
like complex in these cells (data not shown), possibly because of
the differing compositions of the complex in brain and cell lines.
The predominant complex in astrocytes contains Dp71 (6),
whereas cell lines express primarily utrophin complexes (22, 27).
A weaker association exists between utrophin and -dystrogly-
can than between dystrophin and -dystroglycan (22, 28). This
observation may be explained by studies showing that adhesion-
dependent phosphorylation of -dystroglycan abolishes utrophin
binding (29).
Fig. 5. AQP4 expression in cell lines transfected with wild-type (wt) AQP4 or
AQP4 lacking three C-terminal residues (SSV). (A) Transfected HEK293, CHO-
K1, and MDCK cells labeled with anti-AQP4 and analyzed by immunofluores-
cence confocal microscopy show AQP4 wt and SSV localized to the plasma
membrane. Basolateral targeting in MDCK cells was confirmed in vertical
sections (see Insets). (B) AQP4 immunoblot of membrane proteins prepared in
duplicate from transfected HEK293 cells (20 g protein per lane). (C) Expres-
sion of AQP4, neomycin resistance gene (NeoR), and -tubulin (-tub) assessed
by RT-PCR of RNA from transfected HEK293 cells and ethidium bromide
staining of agarose gels.
Fig. 6. Pulse–chase metabolic labeling of stably transfected HEK293 cells
expressing wild-type (wt) AQP4 or AQP4 lacking three C-terminal residues
(SSV). (A) Autoradiograph of cell lysates analyzed by AQP4 immunoprecipi-
tation and SDSPAGE. (B) Graph of the amount of [35S]methionine-labeled
AQP4 protein in the cells during chase. Two independent experiments (open
and filled symbols) are shown. wt AQP4 (E); AQP4 SSV (ƒ).
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Our immunogold analyses of brain from -Syn/ mice indi-
cate that -Syn directly or indirectly anchors AQP4 in astrocyte
membranes facing blood vessels. Absence of -Syn diminishes
perivascular AQP4 expression and reverses the normal concen-
tration difference between perivascular membranes and other
regions. Astrocytes may express other anchoring proteins that
stabilize AQP4 in membranes facing neuropil in the absence of
perivascular -Syn. The presence of multiple AQP4 anchoring
proteins in different distributions may explain why expression of
AQP4 in stomach and kidney persists without -Syn (data not
shown).
Polarized expression of AQP4 in astrocytes may be critical for
brain water homeostasis. We have suggested (30, 31) that AQP4
works in concert with inwardly rectifying K channels to allow
for K siphoning during high neuronal activity. Absence of
-Syn may therefore interfere with the brain’s capacity to handle
excess K and the resulting osmotic gradients, even though total
AQP4 expression is unchanged. In general, syntrophins and the
dystrophin complex may provide the mechanism for the func-
tional and anatomical polarization of astrocytes in the central
nervous system.
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